/BDTX
BDTX Stock - Black Diamond Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$2.54+0.00%
+$0.00 (+0.00%) • Dec 19
53
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.33
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.0
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+215.0%upside
Target: $8.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for BDTX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$2.51 – $2.57
TARGET (TP)$8.00
STOP LOSS$2.34
RISK/REWARD1:27.3
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta3.34
52W High$4.94
52W Low$1.20
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | $-437,000 | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-78,781,000 | $-86,460,000 | $-92,828,000 | $-126,872,000 | $-69,570,000 |
| Net Income | $-69,676,000 | $-82,442,000 | $-91,169,000 | $-125,596,000 | $-67,254,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-1.27 | $-1.88 | $-2.52 | $-3.47 | $-2.04 |
Company Overview
Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including canonical, intrinsic resistance, and acquired resistance mutations; and BDTX-4933, a brain-penetrant inhibitor of oncogenic BRAF class I, II and III alterations. It has a strategic partnership with OpenEye Scientific Software, Inc. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
7
88%
Hold / Neutral
1
13%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
7 Bullish1 Neutral/Bearish
Price Targets
$11
Average Target
↑ 328.1% Upside
Now
$8
Low
$11
Average
$20
High
Based on 8 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 3rd 2025 | Guggenheim | Downgrade | Neutral | - |
| November 18th 2025 | Piper Sandler | Resumed | Overweight | $9 |
| October 16th 2025 | Stifel | Resumed | Buy | $8 |
| September 4th 2025 | Guggenheim | Initiation | Buy | $8 |
| July 1st 2025 | Raymond James | Resumed | Outperform | $11 |
| July 31st 2024 | Raymond James | Initiation | Outperform | $20 |
| July 14th 2023 | Piper Sandler | Initiation | Overweight | - |
| June 30th 2023 | Stifel | Upgrade | Buy | $10← $2 |
| June 28th 2023 | H.C. Wainwright | Upgrade | Buy | $11 |
| June 27th 2023 | Wedbush | Upgrade | Outperform | $10 |
Earnings History & Surprises
BDTXBeat Rate
94%
Last 18 quarters
Avg Surprise
+278.5%
EPS vs Estimate
Beats / Misses
17/1
Last 12 quarters
Latest EPS
$-0.15
Q4 2025
EPS Surprise History
Q1 24
+27.7%
$-0.34vs$-0.47
Q2 24
+20.5%
$-0.35vs$-0.44
Q3 24
+7.7%
$-0.36vs$-0.39
Q4 24
+24.3%
$-0.28vs$-0.37
Q1 25
+9.7%
$-0.28vs$-0.31
Q2 25
+4800.0%
$0.98vs$0.02
Q3 25
+24.0%
$-0.19vs$-0.25
Q4 25
+31.8%
$-0.15vs$-0.22
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Mar 5, 2026 | $-0.18 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-0.22 | $-0.15 | +31.8% | ✓ BEAT |
Q3 2025 | Aug 7, 2025 | $-0.25 | $-0.19 | +24.0% | ✓ BEAT |
Q2 2025 | May 12, 2025 | $0.02 | $0.98 | +4800.0% | ✓ BEAT |
Q1 2025 | Mar 6, 2025 | $-0.31 | $-0.28 | +9.7% | ✓ BEAT |
Q4 2024 | Nov 5, 2024 | $-0.37 | $-0.28 | +24.3% | ✓ BEAT |
Q3 2024 | Aug 6, 2024 | $-0.39 | $-0.36 | +7.7% | ✓ BEAT |
Q2 2024 | May 9, 2024 | $-0.44 | $-0.35 | +20.5% | ✓ BEAT |
Q1 2024 | Mar 12, 2024 | $-0.47 | $-0.34 | +27.7% | ✓ BEAT |
Q4 2023 | Nov 6, 2023 | $-0.49 | $-0.45 | +8.2% | ✓ BEAT |
Q3 2023 | Aug 11, 2023 | $-0.54 | $-0.52 | +3.7% | ✓ BEAT |
Q2 2023 | May 9, 2023 | $-0.61 | $-0.57 | +6.6% | ✓ BEAT |
Q1 2023 | Mar 9, 2023 | $-0.63 | $-0.59 | +6.3% | ✓ BEAT |
Q4 2022 | Nov 8, 2022 | $-0.64 | $-0.60 | +6.3% | ✓ BEAT |
Q3 2022 | Aug 9, 2022 | $-0.68 | $-0.63 | +7.4% | ✓ BEAT |
Q2 2022 | May 11, 2022 | $-0.75 | $-0.70 | +6.7% | ✓ BEAT |
Q1 2022 | Mar 17, 2022 | $-1.01 | $-0.71 | +29.7% | ✓ BEAT |
Q4 2021 | Nov 8, 2021 | $-0.98 | $-0.97 | +1.0% | ✓ BEAT |
Q3 2021 | Aug 12, 2021 | $-0.87 | $-0.95 | -9.2% | ✗ MISS |
Latest News
Guggenheim Downgrades Black Diamond Therapeutic to Neutral
➖ NeutralBenzinga•Dec 4, 2025, 01:48 PM
Black Diamond Therapeutics Shares Resume Trade Following Circuit Breaker Halt
➖ NeutralBenzinga•Dec 3, 2025, 02:44 PM
Black Diamond Therapeutics Shared Topline Data From Its Phase 2 Trial Of Silevertinib In Frontline Non-small Cell Lung Cancer, And Plans For Phase 2 Trial Of Silevertinib In Newly Diagnosed Glioblastoma
📈 PositiveBenzinga•Dec 3, 2025, 12:09 PM
Black Diamond Therapeutics To Present Results From Phase 2 Clinical Study Of Silevertinib On Dec. 3
➖ NeutralBenzinga•Dec 2, 2025, 09:02 PM
Piper Sandler Assumes Black Diamond Therapeutic at Overweight, Announces Price Target of $9
📈 PositiveBenzinga•Nov 18, 2025, 05:15 PM
Black Diamond Therapeutics Files For Mixed Shelf Of Up To $500M; In Addition, Common Stock Offering Of Up To $150M
➖ NeutralBenzinga•Nov 13, 2025, 10:29 PM
Black Diamond Therapeutic Q3 EPS $(0.15) Beats $(0.23) Estimate
📈 PositiveBenzinga•Nov 6, 2025, 12:35 PM
Guggenheim Initiates Coverage On Black Diamond Therapeutic with Buy Rating, Announces Price Target of $8
📈 PositiveBenzinga•Sep 4, 2025, 01:58 PM
Frequently Asked Questions about BDTX
What is BDTX's current stock price?
Black Diamond Therapeutics, Inc. (BDTX) is currently trading at $2.54 per share. The stock has moved +0.00% today.
What is the analyst price target for BDTX?
The average analyst price target for BDTX is $8.00, based on 1 analyst.
What sector is Black Diamond Therapeutics, Inc. in?
Black Diamond Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is BDTX's market cap?
Black Diamond Therapeutics, Inc. has a market capitalization of $0.14 billion, making it a small-cap company.
Does BDTX pay dividends?
No, Black Diamond Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAARD
Aardvark Therapeutics, Inc. Common Stock
$13.77
Mkt Cap: $0.3B
ABEO
Abeona Therapeutics Inc.
$5.11
Mkt Cap: $0.3B
AVTX
Avalo Therapeutics, Inc.
$18.60
Mkt Cap: $0.2B
CRBU
Caribou Biosciences, Inc.
$1.68
Mkt Cap: $0.2B
ENTA
Enanta Pharmaceuticals, Inc.
$15.39
Mkt Cap: $0.3B
FENC
Fennec Pharmaceuticals Inc.
$7.66
Mkt Cap: $0.2B
FHTX
Foghorn Therapeutics Inc.
$5.24
Mkt Cap: $0.3B
IMRX
Immuneering Corporation
$5.65
Mkt Cap: $0.2B
IVA
Inventiva S.A.
$4.21
Mkt Cap: $0.2B
TNYA
Tenaya Therapeutics, Inc.
$0.70
Mkt Cap: $0.1B
Explore stocks similar to BDTX for comparison